Sino Biopharmaceutical (HKG:1177) obtained clinical trial approval for TQC3302, a soft mist inhalation formulation, from China's National Medical Products Administration, a Tuesday Hong Kong bourse filing said.
The inhalation formulation is intended for the maintenance treatment of chronic obstructive pulmonary disease.